Receptor activator of nuclear κB ligand and osteoprotegerin: Where are we now and what about future treatment uses?

Current Opinion in Orthopaedics

Volumn 16, Issue 5, 2005, Pages 370-375

  Schwarz, Edward M ^a   O'Keefe, Regis J ^a   Xing, Lianping ^a   Looney, R John ^a   Ritchlin, Christopher T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Osteoclast; Osteolysis; Osteoporosis; Osteoprotegerin; Receptor activator of nuclear B ligand

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; AMG 162; ANABOLIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RITUXIMAB; TRASTUZUMAB;

ARTHRITIS; BONE DENSITY; BONE METASTASIS; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; IN VITRO STUDY; METABOLIC BONE DISEASE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 33644842664     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bco.0000176422.00241.d4     Document Type: Review

References (44)

1. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289:1504-1508.
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-342.
3. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
4. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315-323.
5. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-2424.
6. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176.
7. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-1268.
8. Kostenuik PJ, Capparelli C, Morony S, et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 2001; 142:4295-4304.
9. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107:1235-1244.
10. Morony S, Capparelli C, Sarosi I, et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61:4432-4436.
11. Capparelli C, Kostenuik PJ, Morony S, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000; 60:783-787.
12. Oyajobi BO, Anderson DM, Traianedes K, et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001; 61:2572-2578.
13. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-309.
14. Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002; 46:785-792.
15. Romas E, Sims NA, Hards DK, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002; 161:1419-1427.
16. Li P, Schwarz EM, O'Keefe RJ, et al. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum 2004; 50:265-276. The authors demonstrate that the release of osteoclast precursors from the bone marrow is central to TNF-induced erosive arthritis.
17. Li P, Schwarz EM, O'Keefe RJ, et al. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 2004; 19:207-213. The authors demonstrate that the TNF-induced osteoclast precursor frequency in blood is independent of RANK signaling, but RANK signaling is required for TNF-induced osteoclastogenesis in vivo.
18. Childs LM, Paschalis EP, Xing L, et al. In vivo RANK signaling blockade using the receptor activator of NF- kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 2002; 17:192-199.
19. Goater JJ, O'Keefe RJ, Rosier RN, et al. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res 2002; 20:169-173.
20. Ulrich-Vinther M, Carmody EE, Goater JJ, et al. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am 2002; 84:1405-1412.
21. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481-1488.
22. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159:1689-1699.
23. Lubberts E, Oppers-Walgreen B, Pettit AR, et al. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum 2002; 46:3055-3064.
24. Lee Y, Schwarz E, Davies M, et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 2003; 21:62-72.
25. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43:250-258.
26. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43:259-269.
27. Romas E, Bakharevski O, Hards DK, et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000; 43:821-826.
28. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821-831.
29. Sakai H, Jingushi S, Shuto T, et al. Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells. Ann Rheum Dis 2002; 61:103-109.
30. Gehrke T, Sers C, Morawietz L, et al. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. Scand J Rheumatol 2003; 32:287-294.
31. Haynes DR, Crotti TN, Potter AE, et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br 2001; 83:902-911.
32. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15:2-12.
33. Schwarz EM, O'Keefe RJ. Breakthough in bone: the molecular mechanism of osteoclast/osteoblast coupling revealed. Curr Opin Orthop 2000; 11:329-335.
34. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349:1207-1215.
35. Ralston SH, Hacking L, Willocks L, et al. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989; 48:396-399.
36. Valleala H, Laasonen L, Koivula MK, et al. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 2003; 30:468-473.
37. Harris WH. The problem is osteolysis. Clin Orthop 1995; 311:46-53.
38. Shanbhag AS, Hasselman CT, Rubash HE. The John Charnley Award: inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop 1997; 344:33-43.
39. Leung A, Scammell B, Lyons A, et al. Alendronate prevents periprosthetic bone loss - 2 year results. Arthritis Rheum 1999; 42(suppl):S270.
40. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16:348-360.
41. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97:887-892.
42. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390:175-179.
43. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19:1059-1066. First clinical trial with anti-RANKL.
44. Cohen SB, McClung MR, Lewiecki EM, et al. AMG 162 administered every 6 months causes rapid and sustained decreases in bone turnover in postmenopausal women with low bone mineral density (BMD). Arthritis Rheum 2004; 50(suppl):S438. First phase II trial of anti-RANKL in women after menopause.